ClinicalTrials.gg
CompletedNCT02721069Updated Jan 31, 2022Results posted

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

A Phase 3 interventional study of NRL-1 in Acute Repetitive Seizures and Breakthrough Seizures, sponsored by Neurelis, Inc.. Completed at 5 sites in United States. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-01-31.

Sponsored by Neurelis, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
175
Allocation
Not applicable
Ages
6 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.

Enrollment
75th of 306
175 · median 56
Started
2016
with 17 others
Phase 3
84 of 395
15 open now
Registered
214th of 395
by date

Among the 395 studies in Seizures with a site in United States, this one is the 75th largest by enrollment of the 306 interventional ones that give a count, is one of 18 that started in 2016, is one of 84 in phase 3, and was the 214th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 6 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Seizures with a site in United States, or all of them as a file.
02

Study summary

This is a 12 month safety study to evaluate the safety of repeated doses of NRL-1

Read the detailed description

This is a Phase 3, repeat dose, open-label, safety study in Epilepsy subjects who have frequent breakthrough seizures or Acute Repetitive Seizures (ARS). NRL-1 will be administered as needed to treat bouts of those seizures over a 12-month period of time. Doses will be defined as 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight. A diary will be used to record the seizure and NRL-1 administration.

03

Conditions studied

  • Acute Repetitive Seizures
  • Breakthrough Seizures

Keywords

  • Seizures
  • Epilepsy
04

Who can participate

Ages eligible
6 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects between the ages of 6 and 65 years, inclusive.
  2. Written to participate in the study.
  3. Subject has a clinical diagnosis of Epilepsy and while on a stable regimen of anti-epileptic medication, still experiences bouts of seizures (e.g. frequent break through seizures or Acute Repetitive Seizures [ARS]), and who, in the opinion of the Investigator, may need benzodiazepine intervention for seizure control at least 1 time a month on average.
  4. Subject has a qualified caregiver or medical professional available that can administer study medication in the event of a seizure.
  5. Subjects having either partial or generalized Epilepsy with motor seizures or seizures with clear alteration of awareness.
  6. Female subjects of , defined as having a menstrual cycle and who are not surgically sterile or less than two (2) years , must complete a pregnancy screen and agree to utilize one of the following forms of during the trial and for 21 days after the last dose of study drug: abstinence, hormonal (oral, transdermal, implant, or injection), barrier (condom, diaphragm with spermicide), intrauterine device (IUD), or vasectomized partner (six months minimum). Subjects must have used the same method for at least one (1) month prior to starting the study.
  7. No abnormal findings in the medical history, on the physical examination or (\<450 msec for males and QTcF\<470 msec for females).
  8. Subjects and caregivers must agree to return to the study site for all study visits and must be willing to comply with all required study procedures.

Exclusion criteria

Exclusion Criteria:

  1. A history of gastrointestinal, renal, hepatic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject.
  2. Subject has had significant traumatic injury, major surgery or open within 30 days prior to study screening.
  3. Subjects with active major depression or a past suicide attempt, or any Suicidal Ideation of 3, 4, or 5 or any Suicidal Behavior in Lifetime using Columbia-Suicide Severity Rating Scale (C-SSRS). The pediatric C-SSRS should be used for subjects age 6 to 11. The adult C SSRS should be used for subjects 12 and greater years of age.
  4. A history of allergic or adverse responses to diazepam or any comparable or similar product.
  5. Participation in a clinical trial other than protocol DIAZ.001.04 within 30 days prior to Day 0. Participation in an observational (non-interventional) study is not excluded as long as there are no scheduling conflicts with this study.
  6. Positive serum pregnancy test (ß-hCG) at screening for subjects age 12 or greater.
  7. Positive blood screen for (HIV), surface antigen (HbSAg), or , or a positive urine screen for alcohol or drugs of abuse, except marijuana use for medical reasons. When marijuana was used for medical reasons in the opinion of the investigator, it is not considered as drug abuse and the patient can be enrolled even if the marijuana metabolites in the urine revealed as positive.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    NRL-1

    Intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.

    Drug: NRL-1

Interventions

  • DrugNRL-1

    Also known as: Intranasal diazepam

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Received NRL-1 (Valtoco)

    Assess the number of participants who received at least one dose of NRL-1 (Valtoco) during the study and comprised the safety population.

    Time frame: 12 months

07

Results

Posted Jan 31, 2022

Participant flow

Participant flow — Overall Study
MilestoneNRL-1
Started175
Completed117
Not completed58

Outcome measures

PrimaryNumber of Participants Who Received NRL-1 (Valtoco)

Assess the number of participants who received at least one dose of NRL-1 (Valtoco) during the study and comprised the safety population.

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants Who Received NRL-1 (Valtoco)
ParticipantsNRL-1 5mgNRL-1 10mgNRL-1 15 mgNRL-1 20mg
Number of Participants Who Received NRL-1 (Valtoco)9544654

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NRL-1 5mg0/9 (0%)2/9 (22.2%)6/9 (66.7%)
NRL-1 10mg0/54 (0%)20/54 (37%)34/54 (63%)
NRL-1 15mg0/46 (0%)15/46 (32.6%)24/46 (52.2%)
NRL-1 20mg1/54 (1.9%)13/54 (24.1%)21/54 (38.9%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventNRL-1 5mgNRL-1 10mgNRL-1 15mgNRL-1 20mg
SeizureNervous system disorders1/911/548/464/54
LethargyNervous system disorders1/90/540/460/54
Status EpilepticusNervous system disorders0/95/541/461/54
PneumoniaInfections and infestations0/94/541/462/54
EpilepsyNervous system disorders0/92/541/462/54
Seizure ClusterNervous system disorders0/90/540/462/54
VomitingGastrointestinal disorders0/92/540/460/54
ScoliosisMusculoskeletal and connective tissue disorders0/92/540/460/54
AmnesiaNervous system disorders0/90/541/460/54
Partial SeizuresNervous system disorders0/90/541/460/54
Most frequent other events
Most frequent other events
EventNRL-1 5mgNRL-1 10mgNRL-1 15mgNRL-1 20mg
InfluenzaInfections and infestations3/95/543/461/54
NasopharyngitisInfections and infestations1/912/543/464/54
DiarrhoeaGastrointestinal disorders2/94/541/462/54
PyrexiaGeneral disorders1/910/543/461/54
Upper Respiratory Tract InfectionInfections and infestations0/99/547/464/54
SeizureNervous system disorders0/94/547/462/54
Urinary Tract InfectionInfections and infestations1/94/543/463/54
Nasal DiscomfortRespiratory, thoracic and mediastinal disorders0/90/544/466/54
VomitingGastrointestinal disorders1/94/542/462/54
SomnolenceNervous system disorders0/95/544/462/54

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)NRL-1
<=18 years92
Between 18 and 65 years82
>=65 years1
Age, Continuous
Age, Continuous(years)NRL-1
Mean22.3 ± 14.87
Sex: Female, Male
Sex: Female, Male(Participants)NRL-1
Female93
Male82
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NRL-1
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander5
Black or African American19
White143
More than one race4
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)NRL-1
United States175
08

Study locations

5 sites
  • Clinical Trials, Inc.
    Little Rock, Arkansas 72205, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • New York University Comprehensive Epilepsy Center
    New York, New York 10016, United States
  • Thomas Jefferson University Hospital Laboratory
    Philadelphia, Pennsylvania 19107, United States
09

References and documents

Publications

  • Cramer JA, Faught E, Davis C, Misra SN, Carrazana E, Rabinowicz AL. Quality-of-life results in adults with epilepsy using diazepam nasal spray for seizure clusters from a long-term, open-label safety study. Epilepsy Behav. 2022 Sep;134:108811. doi: 10.1016/j.yebeh.2022.108811. Epub 2022 Jul 8. PubMed 35816831 ↗
  • Wheless JW, Miller I, Hogan RE, Dlugos D, Biton V, Cascino GD, Sperling MR, Liow K, Vazquez B, Segal EB, Tarquinio D, Mauney W, Desai J, Rabinowicz AL, Carrazana E; DIAZ.001.05 Study Group. Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. Epilepsia. 2021 Oct;62(10):2485-2495. doi: 10.1111/epi.17041. Epub 2021 Aug 21. PubMed 34418086 ↗
  • Miller I, Wheless JW, Hogan RE, Dlugos D, Biton V, Cascino GD, Sperling MR, Liow K, Vazquez B, Segal EB, Tarquinio D, Mauney W, Desai J, Rabinowicz AL, Carrazana E; DIAZ.001.05 Study Group. Consistent safety and tolerability of Valtoco(R) (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long-term, open-label, repeat-dose safety study. Epilepsia Open. 2021 Sep;6(3):504-512. doi: 10.1002/epi4.12494. Epub 2021 May 13. PubMed 34033266 ↗
  • Penovich P, Wheless JW, Hogan RE, Guerra C, Cook DF, Carrazana E, Rabinowicz AL. Examining the patient and caregiver experience with diazepam nasal spray for seizure clusters: Results from an exit survey of a phase 3, open-label, repeat-dose safety study. Epilepsy Behav. 2021 Aug;121(Pt A):108013. doi: 10.1016/j.yebeh.2021.108013. Epub 2021 May 19. PubMed 34022621 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Jun 2020, 50 months.

Results were first posted in Jan 2022, 1 year 7 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's 50 months is close to that.

Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 33 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2016
First posted
Mar 28, 2016
StartActual
Apr 11, 2016
Primary completionActual
Jun 17, 2020
CompletionActual
Jul 23, 2020
Results first posted
Jan 31, 2022
Last update
Jan 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02721069
Lead sponsor
Neurelis, Inc.
Responsible party
Sponsor
First posted
Mar 28, 2016
Start date
Apr 11, 2016
Primary completion
Jun 17, 2020
Completion
Jul 23, 2020
Results posted
Jan 31, 2022
Last update
Jan 31, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazepam

Start the discussion